Literature DB >> 30150142

In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.

Amy W Zawacki1, Ann Dodge2, Kaitlin M Woo3, J Carter Ralphe2, Amy L Peterson4.   

Abstract

BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) level and lipoprotein(a) [Lp(a)] ≥ 50 mg/dL predict atherosclerotic cardiovascular disease (ASCVD) risk in adults with familial hypercholesterolemia (FH), but their role for children with FH is less clear.
OBJECTIVE: This study examined the relationship between elevated Lp(a) and LDL-C levels in a pediatric population with FH and onset of ASCVD in family members.
METHODS: Retrospective review of pediatric patients with FH identified LDL-C, Lp(a), and family history of ASCVD. Logistic regression modeling evaluated the association between the child's Lp(a) and peak LDL-C level with earliest age of ASCVD onset in their family.
RESULTS: One hundred twenty-nine children from 109 families were identified. Children from families with early-onset ASCVD were 3 times more likely to have high Lp(a) than those with a family history of late-onset ASCVD (OR: 3.77, 95% CI: 1.16-12.25, P = .027) but were not more likely to have highly elevated peak LDL-C (≥190 mg/dL) (OR: 0.45, 95% CI: 0.11-1.80, P = .26).
CONCLUSION: Children with FH and family history of early-onset ASCVD were more likely to have Lp(a) ≥50 mg/dL than children with FH and family history of late-onset ASCVD. Family history of early-onset ASCVD was more predictive of a child's Lp(a) level than of a child's peak LDL-C. Measurement of Lp(a) in children with FH may better characterize their cardiovascular risk, particularly when knowledge of family history is limited. Lp(a) testing may also identify children with FH that could benefit from more aggressive management to reduce ASCVD risk.
Copyright © 2018 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk; Familial hypercholesterolemia; Lipid screening; Lipoprotein(a); Low-density lipoprotein cholesterol; Pediatrics; Primordial prevention

Mesh:

Substances:

Year:  2018        PMID: 30150142     DOI: 10.1016/j.jacl.2018.07.014

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  3 in total

Review 1.  Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy.

Authors:  Anne Langsted; Børge G Nordestgaard
Journal:  Curr Atheroscler Rep       Date:  2021-06-20       Impact factor: 5.113

Review 2.  How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?

Authors:  Yu Kataoka; Sayaka Funabashi; Takahito Doi; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2022-01-13       Impact factor: 4.394

Review 3.  Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?

Authors:  Natalie C Ward; Karam M Kostner; David R Sullivan; Paul Nestel; Gerald F Watts
Journal:  J Clin Med       Date:  2019-11-27       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.